We also compared the anti-prostate cancer cell activity between SKI-178 and other SphK1/2 inhibitors, including the SphK1 inhibitor PF-543 [37] and the SphK2 inhibitor ABC294640 [38–41]. Here, SPHK2 is linked to prostate cancer.